New Guidelines Advise Against GLP-1 Weight Loss Drugs During Pregnancy but Allow Early Exposure
New international guidelines based on a systematic review published in Obesity Reviews provide the first practical recommendations for women of reproductive age using GLP-1 family drugs such as Ozempic, Wegovy, Mounjaro, and Saxenda for obesity and diabetes treatment. Experts advise against using these medications during pregnancy due to insufficient safety data, but emphasize that unintended exposure early in pregnancy is not currently considered a reason to terminate the pregnancy.
Obesity before pregnancy is linked to increased risks including ovulation disorders, polycystic ovary syndrome (PCOS), gestational diabetes, hypertension, premature birth, and other complications. Improving metabolic health prior to conception is crucial for reducing risks to both mother and fetus. GLP-1 drugs may enhance fertility by improving insulin sensitivity and reducing chronic inflammation, with studies showing improved ovulation cycles and pregnancy success in women with PCOS. However, it remains unclear whether these benefits stem directly from the drugs or from weight loss.
The official recommendation remains to discontinue GLP-1 medications when planning pregnancy or immediately upon discovering pregnancy, due to lack of large-scale safety studies. Data from 34 studies involving thousands of women exposed to these drugs early in pregnancy showed no increase in birth defects compared to the general population. Regarding breastfeeding, limited data from a small study of eight women treated with semaglutide found no drug in breast milk or adverse effects in infants, but more research is needed before routine use during lactation can be recommended.
Researchers highlight ongoing questions, including the ideal timing to stop treatment before conception, long-term effects on children exposed in utero, and the potential future use of these drugs during pregnancy or breastfeeding. Dr. Osnat Raziel, director of the multidisciplinary obesity treatment center at Asia Medical, summarized that while pre-pregnancy obesity treatment can significantly improve maternal health and pregnancy outcomes, GLP-1 drugs should be stopped when pregnancy is planned or detected, with continued medical follow-up.
